Literature DB >> 32247397

The case for replacing live oral polio vaccine with inactivated vaccine in the Americas.

Jorge A Alfaro-Murillo1, Marí L Ávila-Agüero2, Meagan C Fitzpatrick3, Caroline J Crystal1, Luiza-Helena Falleiros-Arlant4, Alison P Galvani5.   

Abstract

Year:  2020        PMID： 32247397     DOI： 10.1016/S0140-6736(20)30213-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Mucosal vaccine delivery: A focus on the breakthrough of specific barriers.

Authors:  Mengwen Huang; Miaomiao Zhang; Hongbin Zhu; Xiaojiao Du; Jun Wang
Journal:  Acta Pharm Sin B       Date:  2022-07-06       Impact factor: 14.903

2.  Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines.

Authors:  Yoshikazu Honda-Okubo; Jeremy Baldwin; Nikolai Petrovsky
Journal:  Pathogens       Date:  2021-04-21

3.  Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.

Authors:  Ananda S Bandyopadhyay; Chris Gast; Luis Rivera; Xavier Sáez-Llorens; M Steven Oberste; William C Weldon; John Modlin; Ralf Clemens; Sue Ann Costa Clemens; Jose Jimeno; Ricardo Rüttimann
Journal:  Lancet Infect Dis       Date:  2020-10-23       Impact factor: 25.071

4.  Polio eradication vaccine investment: how do we ensure polio vaccines are available to keep the world polio-free after transmission of wild poliovirus (wPV) has been interrupted?

Authors:  Amie Batson; Awi Federgruen; Nirmal Kumar Ganguly; Amanda Glassman; Simba Makoni; Stanley Plotkin
Journal:  BMJ Glob Health       Date:  2021-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.